Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADT, Docetaxel, and Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer
NCT03246347Phase 2Active, not recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2017
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Wake Forest University Health Sciences. Primary endpoint: PSA Complete Response Rate at 52 weeks. Started Aug 2017; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03246347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246347.